Dystonia

Netflix' "Take Care of Maya" Brought the Disease CRPS Into Public Awareness, Now Parents Are Asking if They or Their Children Have It

Retrieved on: 
Friday, July 14, 2023
Complex regional pain syndrome, Clothing, Foot, Weakness, Dystonia, Maya, CRPS, Multimedia, Temperature, Persistent, Movement, Paralysis, Pain, Motion, Political moderate, System, Skin temperature, Trauma, Netflix, News, Pediatrics, Motor disorder, Nursing, Online shopping

MILFORD, Conn., July 14, 2023 /PRNewswire/ -- CRPS, or Complex Regional Pain Syndrome, is a serious, incurable disease that may not be as rare as it is rarely diagnosed. The good news is that if it is diagnosed early, it can be put into remission, often for a lifetime. RSDSA, the international CRPS support group, shows you how to tell if you or a loved one may have CRPS and where to get the right help. Just follow this link to find out if You or Your Child Has CRPS.

Key Points: 
  • Here is how to self-diagnose the signs of CRPS and where to look for the right medical help.
  • MILFORD, Conn., July 14, 2023 /PRNewswire/ -- CRPS, or Complex Regional Pain Syndrome, is a serious, incurable disease that may not be as rare as it is rarely diagnosed.
  • The good news is that if it is diagnosed early, it can be put into remission, often for a lifetime.
  • The Netflix documentary "Take Care of Maya" has raised awareness of, and many questions about CRPS.

ZyVersa Therapeutics Announces Article Published in Biomaterials Addressing the Critical Role of Inflammasome Activation in Neuroinflammation Resulting from Intracortical Implants

Retrieved on: 
Wednesday, April 19, 2023
Epilepsy, Microelectrode, ASC, University, Inflammasome, AIM2, Associate professor, DSM-IV codes, ME, Quality of life, NLRP3, Dystonia, Biomedical engineering, Essential tremor, Wallace H. Coulter Department of Biomedical Engineering, Parkinson's disease, Biomedicine, Patient, NLRP1, Brain, Invention, NLRC4, Therapy, Disease, Medical imaging, Pharmaceutical industry, Medical device, Biomaterial, Medicine

Deep brain stimulation devices are intracortical implants used to treat disabling symptoms of neurological conditions such as Parkinson's disease, epilepsy, essential tremor, and dystonia

Key Points: 
  • Deep brain stimulation devices are intracortical implants used to treat disabling symptoms of neurological conditions such as Parkinson's disease, epilepsy, essential tremor, and dystonia
    WESTON, Fla., April 19, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, is pleased to announce that world renowned inflammasome researchers and inventors of ZyVersa’s Inflammasome ASC Inhibitor IC 100 from the University of Miami Miller School of Medicine have published a scientific paper in the peer-reviewed journal, Biomaterials.
  • In the paper titled, “Activation of inflammasomes and their effects on neuroinflammation at the microelectrode-tissue interface in intracortical implants,” the researchers reported:
    Multiple types of inflammasome sensor molecules (NLRP1, NLRP3, AIM2, and NLRC4) were upregulated following ME implant injury
    NLRP1 and NLRP3, which were upregulated by 48 hours and remained distinctly elevated at 4 weeks, play a vital role in activation of inflammasome complexes during acute and sub-chronic periods following ME-induced injury
    In addition to sensor molecules, ASC and Caspase-1 were persistently elevated throughout the implant duration
    Sustained presence of gasdermin D provides evidence of elevated pyroptosis (“cell death”) occurring at the injury site, which coincided with a decrease in neuronal density
    “Deep brain stimulation is an important therapeutic option to help maintain quality of life in patients with movement disorders whose symptoms are not effectively controlled by medication,” stated Dr. Abhishek Prasad, Associate Professor, the Department of Biomedical Engineering at the University of Miami Miller School of Medicine.
  • “Our results not only demonstrate that continuous activation of inflammasomes contribute to neuroinflammation at the ME-tissue interface, but also reveal the therapeutic potential of targeting inflammasomes to attenuate the foreign body response to cortical implants.”
    “The research published in Biomaterials provides additional support for the therapeutic potential of ZyVersa’s proprietary monoclonal antibody inflammasome ASC inhibitor, IC 100, in neurological injury and disease,” indicated Stephen C. Glover, ZyVersa’s Co-founder, Chairman, CEO and President.
  • “Preclinical studies have demonstrated reduced inflammatory activity and/or improved outcomes in two different models of brain injury, spinal cord injury, age-related inflammation Alzheimer’s disease, and multiple sclerosis.”

$9,427.7 Million Neuromodulation Devices Markets - Global Forecast To 2029 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 19, 2023
Medical Devices, Health, Epilepsy, SNS, VNS, Urinary incontinence, Mood disorder, Anxiety, PD, Prevalence, OCD, Obstructive sleep apnea, Central sleep apnea, Hospital, DSM-IV codes, Ageing, Stroke, Incontinence, Spinal cord, OSA, Multiple sclerosis, Parkinson, CNS, Central nervous system, Government, Pain, Pain management, DBS, Incidence, Parkinson's disease, Spinal cord stimulator, Chronic pain, Gastroenterology, Myenteric plexus, Alzheimer's disease, Obsessive–compulsive disorder, Growth, Urology, Eagle syndrome, Cranial nerves, Disease, SCS, Video game, Pharmaceutical industry, Medical device, Speciality chemicals, Gastroparesis, Depression, Dystonia

The "Neuromodulation Devices Global Market- Forecast To 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Neuromodulation Devices Global Market- Forecast To 2029" report has been added to ResearchAndMarkets.com's offering.
  • The neuromodulation devices global market is expected to reach $9,427.7 million by 2029 growing at a high single digit CAGR from 2022 to 2029.
  • The emergence of neuromodulation as add-on therapy, technological innovations in neuromodulation, expansion in emerging markets and the rise in the number of clinical studies performed provides immense opportunities to the neuromodulation market.
  • Based on the product, the neuromodulation global market is segmented into invasive neuromodulation devices and non-invasive neuromodulation devices.

Global Wilson's Disease Drugs Market to 2030: Players Include Kadmon Holdings, Merck & Co, Noble Pharma and Teva Pharmaceutical Industries - ResearchAndMarkets.com

Retrieved on: 
Friday, April 14, 2023
Biotechnology, Pharmaceutical, Health, Seizure, Triethylenetetramine, Male, Fatigue, Psychosis, Hepatitis, Partnership, Wilson's disease, Tremor, Zinc, Prevalence, Schizophrenia, Ataxia, Mutation, Dystonia, Zinc acetate, Brain, Data mining, Merck & Co., DSM-IV codes, Person, Wilson, Dietary supplement, Patient, Drug discovery, Liver, Diagnosis, Copper, Basal ganglia, News, Bipolar disorder, Disease, Penicillamine, Female, Pharmaceutical industry, Parkinsonism

It is very important for the accurate diagnosis of Wilson's disease or could lead to fatal consequences if not done appropriately.

Key Points: 
  • It is very important for the accurate diagnosis of Wilson's disease or could lead to fatal consequences if not done appropriately.
  • The early diagnosis of Wilson's disease is primarily based on the multiple indications such as hepatic, neuropsychiatric, ophthalmic and others.
  • Product portfolio gives an idea about the different dietary supplements enriched in zinc primarily used for the management of Wilson's disease.
  • The manufacturers that are active in the treatment of Wilson's disease are Kadmon Holdings, Inc., Merck & Co., Noble Pharma Co., Ltd., Teva Pharmaceutical Industries Limited, Tsumura & Co., Valeant Pharmaceuticals International, Inc., VHB Life Sciences, Inc. and Wilson Therapeutics AB.

UNRAVEL BIOSCIENCES RECEIVES GRANT TO SUPPORT NEURODEGENERATIVE TARGET DISCOVERY

Retrieved on: 
Wednesday, March 29, 2023
DNA, CRISPR, MGH, Drug development, Therapy, CSO, Dystonia, XDP, Research, Xenopus, Patient, X-linked dystonia parkinsonism, Hospital, TAF1, Health, Massachusetts General Hospital, Phenotype, Disease, Pharmaceutical industry

BOSTON, March 29, 2023 /PRNewswire/ -- Unravel Biosciences, Inc., ("Unravel"), a therapeutics company that leverages a machine-learning model of human health to advance drugs for complex diseases, today announced receipt of grant funding from the Collaborative Center for X-linked Dystonia Parkinsonism (CCXDP) at Massachusetts General Hospital (MGH) to enable rapid target discovery for XDP.

Key Points: 
  • BOSTON, March 29, 2023 /PRNewswire/ -- Unravel Biosciences, Inc., ("Unravel"), a therapeutics company that leverages a machine-learning model of human health to advance drugs for complex diseases, today announced receipt of grant funding from the Collaborative Center for X-linked Dystonia Parkinsonism (CCXDP) at Massachusetts General Hospital (MGH) to enable rapid target discovery for XDP.
  • The current award will advance target discovery and validation to enable new drug development tailored to the needs to XDP patients.
  • "We are pleased with the opportunity to continue this collaboration with CCXDP," said Frederic Vigneault, Ph.D., Unravel Co-Founder and CSO.
  • Our ambition by the end of this grant is to nominate a candidate that can move quickly to clinical trials."

Medical Park Hospitals Group MD, Assoc. Prof. Neurosurgeon, Sait Öztürk has successfully accomplished Brain Pacemaker surgery while awake and watching cartoons to DYSTONIA PATIENT ZEYNEP

Retrieved on: 
Wednesday, March 15, 2023
Suicide, Hospital, Health, Neurosurgery, Hope, Depression, File association, Cartoon, Tremor, Medical device, Dystonia, Medical Park

The patient's surgery was performed Medical Park, Turkey's health power with 27 Hospitals and thousands of doctors.

Key Points: 
  • The patient's surgery was performed Medical Park, Turkey's health power with 27 Hospitals and thousands of doctors.
  • Giving information about the patient's surgery process, Medical Park Bahçelievler Hospital Brain and Neurosurgery Specialist Assoc.
  • Prof. Dr. Sait Öztürk said: "Dystonia is a very rare disease.
  • She regained both her health and the art of painting after a successful neurosurgery performed at Dr. Sait Öztürk.

Medical Park Hospitals Group MD, Assoc. Prof. Neurosurgeon, Sait Öztürk has successfully accomplished Brain Pacemaker surgery while awake and watching cartoons to DYSTONIA PATIENT ZEYNEP

Retrieved on: 
Wednesday, March 15, 2023
Suicide, Hospital, Health, Neurosurgery, Hope, Depression, File association, Cartoon, Tremor, Medical device, Dystonia, Medical Park

The patient's surgery was performed Medical Park, Turkey's health power with 27 Hospitals and thousands of doctors.

Key Points: 
  • The patient's surgery was performed Medical Park, Turkey's health power with 27 Hospitals and thousands of doctors.
  • Giving information about the patient's surgery process, Medical Park Bahçelievler Hospital Brain and Neurosurgery Specialist Assoc.
  • Prof. Dr. Sait Öztürk said: "Dystonia is a very rare disease.
  • She regained both her health and the art of painting after a successful neurosurgery performed at Dr. Sait Öztürk.

Global Psychiatry Partnering Deal Trends, Players and Financials Directory/Report 2016-2023 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 14, 2023
Biotechnology, Pharmaceutical, Health, Mental Health, Tardive dyskinesia, Chapter Five, A-Z, Chapter Six, Chronic fatigue syndrome, Bulimia nervosa, Tourette syndrome, Chapter Two, Research, Sleep disorder, Alzheimer's disease, Vascular dementia, Personality disorder, Confidentiality, Learning disability, Sleep apnea, Anxiety disorder, Three-body problem, Eating disorder, Cognitive deficit, Psychiatry, Chapter One, Panic disorder, Obsessive–compulsive disorder, Hyperlink, Intellectual property, Collection, Attention deficit hyperactivity disorder, Chapter Four, Chapter Three, Bipolar disorder, Narcolepsy, Directory, Pharmaceutical industry, Lease, Risk management, Commercial property, Property management, Anorexia nervosa, Dystonia, Akathisia, Autism spectrum, Dementia, Insomnia, Depression, Schizophrenia, Delirium

The "Global Psychiatry Partnering 2016-2023: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Psychiatry Partnering 2016-2023: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.
  • The report takes readers through the comprehensive psychiatry disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering psychiatry deals.
  • Chapter 6 provides a comprehensive directory of all psychiatry partnering deals by specific psychiatry target announced since 2016.
  • In addition, a comprehensive appendix is provided with each report of all psychiatry partnering deals signed and announced since 2016.

Memorial Neurosurgery Team First in South Florida to Perform Robotic-Assisted "Asleep" Deep Brain Stimulation to Treat Parkinson's Disease

Retrieved on: 
Monday, February 20, 2023
Neurosurgery, Electrode, Brain, Neurology, Patient, CT, Safety, Movement disorder, Tremor, ZEUS robotic surgical system, Skin, ROSA, DBS, DSM-IV codes, Parkinson's disease, Deep brain stimulation, Dystonia, Medical device, Nursing

HOLLYWOOD, Fla., Feb. 20, 2023 /PRNewswire-PRWeb/ -- Deep brain stimulation (DBS) is a proven surgical treatment where a neurosurgeon implants electrodes in a specific area of the brain to help relieve tremors and symptoms of stiffness and slowness in patients who have Parkinson's disease or another movement disorder, such as dystonia. However, traditional DBS surgery can be unpleasant and painful, as it is performed while the patient is awake and requires individuals to stop taking any medications to control their movement disorders.

Key Points: 
  • Memorial Neuroscience Institute is the first in South Florida to offer an advanced method of DBS that is performed while the patient is comfortably asleep under general anesthesia.
  • "Our team of neurologists, neuropsychologists and neurosurgeons perform a detailed evaluation of each patient to determine their care plan," said Dr. Harsh Gupta, neurologist who specializes in movement disorders at Memorial Neuroscience Institute.
  • Patients who want to learn more about DBS should speak with their neurologist or primary care physician who may refer them to Memorial Neuroscience Institute.
  • To learn more about Memorial Neuroscience Institute, visit http://www.mhs.net/neuroscience or call 954-265-9500.

Epilepsy Devices Market to Reach USD 1.11 Billion, Globally, by 2031 at 5.1% CAGR: Allied Market Research

Retrieved on: 
Thursday, January 12, 2023
Hospital, Seizure, National Association Medical Staff Services, Electromyography, Parkinson's disease, EEG, Epilepsy, Deep brain stimulation, Deep, Degenerative disease, Government, Quality of life, Growth, Patient, Prevalence, Physician, Vagus nerve stimulation, Dystonia, EKG, Investment, COVID-19, Pharmaceutical industry, Medical device, Electrocardiography, Accelerometer

PORTLAND, Ore., Jan. 12, 2023 /PRNewswire/ -- Allied Market Research published a report, titled, "Epilepsy Devices Market by Product Type (conventional and wearable devices, EEG, Electrocardiography (EKG), Surface Electromyography (sEMG), Video Detection Systems, Others), by Technology (Deep brain Stimulation, Vagus Nerve Stimulation, Responsive Neurostimulation, Accelerometry), by End User (Hospitals, Clinics, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031" According to the report, the global epilepsy devices industry generated $675.23 million in 2021, and is estimated to reach $1.11 billion by 2031, witnessing a CAGR of 5.1% from 2022 to 2031. The report offers a detailed analysis of changing market trends, top segments, key investment pockets, value chains, regional landscapes, and competitive scenarios.

Key Points: 
  • Rise in the prevalence of old age population that are more vulnerable to epilepsy and increase in awareness regarding the use of epilepsy devices drives the growth of the global epilepsy devices market.
  • Rise in the prevalence of old age population that are more vulnerable to epilepsy and increase in awareness regarding the use of epilepsy devices drives the growth of the global epilepsy devices market.
  • Disruptions in production, development, and supply of epilepsy devices hampered the growth of medical device businesses of companies across the world, thus impacting the global epilepsy devices market negatively.
  • By region, North America held the highest revenue in 2021, accounting for around two-fifths of the global epilepsy devices market share.